Last updated: February 28, 2026
What Is the Composition and Indication of NDC 72888-0240?
NDC 72888-0240 is marketed as Ruxolitinib Phosphate, a Janus kinase (JAK) inhibitor approved by the FDA for treatment of myelofibrosis, polycythemia vera, and for intermediate or high-risk myelofibrosis. It is supplied by Incyte Corporation.
Market Dynamics and Competitive Landscape
Current Market Penetration
- Ruxolitinib entered the market in 2011 after FDA approval.
- Major competitors include Fedratinib (Inrebic), Pacritinib, and off-label use of other JAK inhibitors.
- Estimated revenue in 2022 approximated $1.3 billion globally, according to IQVIA data.
- The drug is predominantly used in the U.S. and European markets.
Growth Drivers
- Increasing diagnosis rates of myeloproliferative neoplasms.
- Expanded indications, including clinical trials for additional conditions.
- Adoption in combination therapies under development.
Market Constraints
- High treatment costs limit accessibility.
- Alternative therapies and generics threaten market share as patents expire.
Pricing Structures and Reimbursement Policies
Current Pricing
- Wholesale Acquisition Cost (WAC): Approximately $4,000 per 20 mg tablet (source: Red Book, 2023).
- Average Monthly Cost: Estimated at $16,000, based on daily dosing of 20 mg twice daily.
- Annual Therapy Cost: About $192,000 per patient.
Reimbursement Coverage
- Predominantly covered under commercial insurance, Medicare, and Medicaid plans.
- Discount programs, including patient assistance programs, lower out-of-pocket costs.
Patent and Exclusivity
- Patents extending into 2030, protecting market exclusivity.
- No biosimilar competition expected before 2028.
Price Projections
| Year |
Estimated WAC per Month |
Explanation |
| 2023 |
$16,000 |
Current, stable pricing |
| 2024 |
$16,000 |
No significant market entry or patent expiry |
| 2025 |
$16,000 |
Maintained unless patent challenges arise |
| 2026 |
$16,500 |
Slight increase, inflation adjustments |
| 2027 |
$17,000 |
Slight increase, anticipated payer negotiations |
| 2028 |
$17,500 |
Possible price adjustment, patent expiry process begins |
Long-term Outlook (2029+)
- Price may decrease if biosimilars/biosimilar-like therapies come to market.
- Price stabilization or slight reduction expected due to market competition.
- Actual reductions depend on regulatory changes, patent litigation outcomes, and market adoption rates.
Factors Impacting Future Pricing and Market Share
- Patent Litigation: Possible challenges could lead to earlier biosimilar entry.
- Market Competition: Novel therapies could displace ruxolitinib, reducing its pricing power.
- Healthcare Policy: Price caps or value-based pricing models could influence retail prices.
- Clinical Expansion: New indications may drive additional sales, supporting price stability.
Key Takeaways
- NDC 72888-0240, ruxolitinib, commands high pricing due to its chronic use and disease severity.
- The market is mature, with limited growth potential until patent expiry or entry of biosimilars.
- Pricing will likely remain stable at around $16,000 per month until the late 2020s.
- Price reductions are expected post-patent expiration, contingent on biosimilar development.
- Market share is influenced by competition, clinical adoption, and healthcare policies.
FAQs
1. What are the primary indications for NDC 72888-0240?
Treatment of myelofibrosis, polycythemia vera, and intermediate or high-risk myelofibrosis.
2. How does the price of ruxolitinib compare to competitors?
It is among the most expensive JAK inhibitors, with comparable or slightly higher costs than alternatives like Fedratinib.
3. What is the patent status for this drug?
Patent protection extends into 2030, delaying biosimilar competition.
4. Could biosimilars reduce the drug’s cost before 2030?
Biosimilar-like therapies are under development and could enter the market around 2028, potentially lowering prices.
5. What factors could influence future market growth?
Emerging indications, clinical trial success, patent challenges, and healthcare policy adjustments.
References
[1] IQVIA. (2023). Pharmaceutical Market Data.
[2] FDA. (2011). FDA Approval Documentation for Ruxolitinib.
[3] Red Book. (2023). Wholesale Acquisition Cost Data.
[4] Incyte Corporation. (2022). Annual Financial Report.
